Since no correlation was found between the post-diagnostic use of β-blockers and breast cancer progression [103], these observations implied that the βAR-dependent mechanisms leading to recurrence might mainly affect early stages of metastatic dissemination. Here, ADRB2 is linked to breast cancer.